Stryker(SYK)

Search documents
AHCO or SYK: Which Is the Better Value Stock Right Now?
ZACKS· 2025-04-29 16:45
Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Stryker (SYK) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates ...
ISRG vs. SYK: Which Robotic-Device Innovator Is a Better Buy?
ZACKS· 2025-04-29 14:15
Core Insights - Robotic-assisted surgery is becoming essential in modern healthcare, with Intuitive Surgical and Stryker leading the market [1][2] - Both companies are heavily investing in innovation and global expansion, making them attractive for investors [2] Market Position and Differentiation - Intuitive Surgical pioneered robotic surgery with the da Vinci platform, while Stryker entered the market through the acquisition of Mako Surgical [3] - Intuitive holds nearly 80% of global surgical robotics volume, contrasting with Stryker's focus on orthopedic robotics with over 1.5 million Mako procedures [4] Revenue & Growth Trends - Intuitive's Q1 2025 revenues increased by 19% to $2.25 billion, with da Vinci procedures growing by 17% [5] - Stryker's MedSurg/Neurotechnology sales rose by 10.6% to $3.89 billion in Q4 2024, while Orthopaedics climbed by 10.8% to $2.55 billion [5] - The global robotic surgery market is projected to grow at a CAGR of 16.5% through 2029, driven by minimally invasive trends and aging populations [6] Estimates Comparison for ISRG & SYK - Zacks Consensus Estimate for ISRG's fiscal 2025 sales and EPS implies a year-over-year improvement of 15.6% and 7.1% respectively [7] - Zacks Consensus Estimate for Stryker's 2025 sales and EPS implies a year-over-year improvement of 8.6% and 10.4% respectively [10] Innovation Driving Growth - Intuitive Surgical is investing in next-generation platforms like the Ion endoluminal system for robotic bronchoscopy [12] - Stryker is enhancing its Mako SmartRobotics suite with AI-driven 3D CT planning and AccuStop haptic feedback [13] Price Performance & Valuation - Year-to-date price performance shows ISRG shares have lost 1.5%, while SYK shares have gained 1.8% [15] - Intuitive Surgical's dominance and sustainable revenue growth position it well, while Stryker's innovations fuel growth in the joint-replacement robotics niche [17] Zacks Rank & Style Score - Both companies currently hold a Zacks Rank 3 (Hold), complicating the investment decision [18] - ISRG's style score of 'F' indicates expensive valuation and low growth potential, while SYK's style score of 'C' suggests strong growth prospects [19]
Stryker to participate in the Bank of America Securities 2025 Global Healthcare Conference
Globenewswire· 2025-04-29 12:00
Group 1 - Stryker will participate in the Bank of America Securities 2025 Global Healthcare Conference on May 13, 2025, in Las Vegas, Nevada [1] - The presentation will be led by Preston Wells, CFO, and Jason Beach, VP of Finance and Investor Relations, scheduled for 1:40 p.m. Pacific Time [1] - A live webcast and replay of the presentation will be available on Stryker's website and archived on the Investor Relations page [2] Group 2 - Stryker is a global leader in medical technologies, focusing on improving healthcare through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [3] - The company impacts over 150 million patients annually through its offerings [3] - Additional information about Stryker can be found on their official website [3]
Gear Up for Stryker (SYK) Q1 Earnings: Wall Street Estimates for Key Metrics
ZACKS· 2025-04-28 14:21
Core Insights - Stryker (SYK) is expected to report quarterly earnings of $2.73 per share, a 9.2% increase year-over-year, with revenues forecasted at $5.7 billion, reflecting an 8.8% increase [1] Earnings Projections - The consensus EPS estimate has been revised down by 0.3% over the past 30 days, indicating a collective reassessment by analysts [2] - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock performance [3] Revenue Estimates - Analysts predict 'Net Sales by Business- Orthopaedics and Spine' will reach $2.31 billion, a 2.8% increase from the prior year [5] - 'Net Sales by Business- MedSurg and Neurotechnology' is expected to be $3.41 billion, indicating a 13.7% increase year-over-year [5] Segment Performance - 'Net Sales by Business- Orthopaedics and Spine- Knees' is projected at $624.41 million, a 6.2% increase [6] - 'Net Sales by Business- Orthopaedics and Spine- Spine' is expected to decline to $172.83 million, a significant drop of 42.4% [6] Geographic Sales - 'Net Sales by Geography- International' is estimated at $1.44 billion, reflecting an 8.5% increase [7] - 'Net Sales by Geography- United States' is forecasted at $4.25 billion, indicating an 8.6% year-over-year change [7] - 'Net Sales by Geography- Orthopaedics and Spine- United States' is expected to be $1.60 billion, showing a slight decline of 0.2% [7] Specific Product Lines - 'Net Sales by Geography- Orthopaedics and Spine- Trauma and Extremities- United States' is projected at $669.94 million, a 9.7% increase [8] - 'Net Sales by Geography- Orthopaedics and Spine- Knees- United States' is expected to be $455.61 million, reflecting a 6.2% increase [8] - 'Net Sales by Geography- Orthopaedics and Spine- Hips- United States' is projected at $265.89 million, indicating a 5.9% increase [9] Overall Market Performance - Over the past month, Stryker shares have recorded a return of +0.2%, outperforming the Zacks S&P 500 composite, which declined by -4.3% [10]
美国品牌霸榜,2025全球医疗仪器设备品牌价值榜公布
仪器信息网· 2025-04-28 09:05
导读: 英国品牌评估机构"品牌金融"(Brand Finance)最新发布了2025全球医疗设备品牌价值榜(Medical Devices Brands 2025)。美 敦力、费森尤斯、雅培名列前三位。 特别提示 微信机制调整,点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标,否则很可能无法看到我们的推送。 | #1 | Medtronic | $7.4 bn | +2% | | --- | --- | --- | --- | | #2 | Fresenius | $7.3 bn | -5% | | #3 | Abbott | $5.8 bn | +6% | | #4 | Philips | $5.5 bn | +24% | | #5 | Stryker | $5.2 bn | +22% | | #6 | Siemens Healthineers | $5.2 bn | +17% | | #7 | BD | $3.3 bn | -5% | | #8 | Boston Scientific | $3.2 bn | +12% | | #d | GE HealthCare | $3.1 bn | | 榜 ...
The Zacks Analyst Blog Bank of America, Chevron, Stryker, Value Line and Sypris
ZACKS· 2025-04-15 11:50
Group 1: Bank of America Corporation (BAC) - Bank of America shares have gained +2.5% over the past year, underperforming the Zacks Financial - Investment Bank industry's gain of +20.4% [3] - Non-interest income is projected to rise only 3.4% in 2025, while total non-interest expenses are expected to increase by 3% [4] - Net interest income (NII) is anticipated to grow at a CAGR of 5.3% over the next three years, with total revenues projected to increase by 4.8% in 2025 [5] Group 2: Chevron Corporation (CVX) - Chevron shares have declined -6.2% over the past six months, compared to the Zacks Oil and Gas - Integrated - International industry's decline of -11.9% [6] - The planned acquisition of Hess Corporation is expected to enhance Chevron's presence in oil-rich Guyana, although the company faces challenges from oil price fluctuations and high valuation [7] Group 3: Stryker Corporation (SYK) - Stryker shares have gained +4.3% over the past year, slightly underperforming the Zacks Medical - Products industry's gain of +5.5% [8] - Growth drivers include rising demand for robotic-assisted procedures, hospital capital expenditures, and international expansion, supported by the Mako SmartRobotics platform [9] - However, foreign exchange volatility and supply chain disruptions may impact earnings, alongside increasing competition in the MedTech sector [10] Group 4: Value Line, Inc. (VALU) - Value Line shares have outperformed the Zacks Financial - Investment Management industry over the past year, with a gain of +10% compared to +6.4% [11] - The company has robust cash generation, with cash balances increasing to $27.1 million from $6.1 million year-over-year, supporting dividends and growth investments [11] - However, core publishing revenue declined to $26.7 million, and customer concentration poses a risk [13] Group 5: Sypris Solutions, Inc. (SYPR) - Sypris Solutions shares have gained +3.6% over the past year, underperforming the Zacks Electronics - Miscellaneous Services industry's gain of +36.3% [14] - The company benefits from a long-term supply agreement with a global OEM, providing stable revenues as a sole-source supplier [14] - However, liquidity challenges and rising costs may constrain financial flexibility, while competitive pressures in aerospace heighten vulnerability [16]
Stryker to announce financial results for its first quarter of fiscal year 2025
Newsfilter· 2025-04-07 12:00
Portage, Michigan, April 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2025 on Thursday, May 1, 2025. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's first quarter that ended March 31, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, May 1, 2025, to discuss its firs ...
Viscogliosi Brothers Completes Acquisition of U.S. Spine Business from Stryker, Creating VB Spine, LLC
Newsfilter· 2025-04-01 20:26
VB Spine is a Strategic Partner to Stryker with Access to Mako Spine and Copilot Marc, John and Anthony Viscogliosi Lead VB Spine as Co-Chief Executive Officers NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Viscogliosi Brothers, LLC, a family-owned investment office specializing in the neuro-musculoskeletal space, today announced the successful completion of its previously announced acquisition of the U.S. spine business from Stryker (NYSE:SYK). The business will operate as a standalone company under the nam ...
Viscogliosi Brothers Completes Acquisition of U.S. Spine Business from Stryker, Creating VB Spine, LLC
GlobeNewswire News Room· 2025-04-01 20:26
VB Spine is a Strategic Partner to Stryker with Access to Mako Spine and Copilot Marc, John and Anthony Viscogliosi Lead VB Spine as Co-Chief Executive Officers NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Viscogliosi Brothers, LLC, a family-owned investment office specializing in the neuro-musculoskeletal space, today announced the successful completion of its previously announced acquisition of the U.S. spine business from Stryker (NYSE: SYK). The business will operate as a standalone company under the na ...
Stryker completes sale of U.S. spinal implants business
Globenewswire· 2025-04-01 20:05
Portage, Michigan, April 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC, as part of the newly formed company VB Spine, LLC. Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve ...